Personalis, Inc. announced that Deanna Church, Ph.D., has joined its R&D team, and Robert Nussbaum, M.D., Professor of Medicine and Chief of the Division of Genomic Medicine at UCSF, has joined its Clinical and Scientific Advisory Board. Dr. Nussbaum will bring his deep expertise in medical genetics to guide development of Personalis' next-generation sequencing (NGS) based clinical services. Dr. Church comes to Personalis from the NCBI where she helped lead development of the newest Human Reference GRCh38 as well as genomic tools used by scientists worldwide.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.25 USD | +11.94% | +45.16% | +7.14% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.14% | 117M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+46.00% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- PSNL Stock
- News Personalis, Inc.
- Personalis Announces Appointments to Clinical and Scientific Advisory Board